Free Trial

Adverum Biotechnologies (ADVM) Competitors

Adverum Biotechnologies logo
$2.45 -0.07 (-2.78%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$2.48 +0.02 (+1.02%)
As of 08/7/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADVM vs. RAPT, MDWD, TLSA, ELDN, DMAC, YMAB, NLTX, CRBU, FDMT, and ALMS

Should you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Rapt Therapeutics (RAPT), MediWound (MDWD), Tiziana Life Sciences (TLSA), Eledon Pharmaceuticals (ELDN), DiaMedica Therapeutics (DMAC), Y-mAbs Therapeutics (YMAB), Neoleukin Therapeutics (NLTX), Caribou Biosciences (CRBU), 4D Molecular Therapeutics (FDMT), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

Adverum Biotechnologies vs. Its Competitors

Adverum Biotechnologies (NASDAQ:ADVM) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Rapt Therapeutics has higher revenue and earnings than Adverum Biotechnologies. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adverum Biotechnologies$1M51.18-$130.93M-$6.40-0.38
Rapt Therapeutics$1.53M110.81-$129.87M-$19.20-0.53

Adverum Biotechnologies currently has a consensus price target of $23.80, suggesting a potential upside of 871.43%. Rapt Therapeutics has a consensus price target of $20.57, suggesting a potential upside of 100.70%. Given Adverum Biotechnologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Adverum Biotechnologies is more favorable than Rapt Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adverum Biotechnologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Rapt Therapeutics
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.57

Rapt Therapeutics' return on equity of -81.47% beat Adverum Biotechnologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Adverum BiotechnologiesN/A -130.53% -66.31%
Rapt Therapeutics N/A -81.47%-70.24%

In the previous week, Rapt Therapeutics had 2 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 3 mentions for Rapt Therapeutics and 1 mentions for Adverum Biotechnologies. Rapt Therapeutics' average media sentiment score of 0.77 beat Adverum Biotechnologies' score of 0.00 indicating that Rapt Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Adverum Biotechnologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rapt Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

48.2% of Adverum Biotechnologies shares are owned by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are owned by institutional investors. 6.0% of Adverum Biotechnologies shares are owned by insiders. Comparatively, 2.4% of Rapt Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Adverum Biotechnologies has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.

Summary

Adverum Biotechnologies and Rapt Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Adverum Biotechnologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADVM vs. The Competition

MetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$52.65M$2.98B$5.48B$9.57B
Dividend YieldN/A2.46%3.99%4.17%
P/E Ratio-0.3817.9729.8925.14
Price / Sales51.18262.52421.4486.79
Price / CashN/A41.8335.9458.58
Price / Book0.727.238.125.59
Net Income-$130.93M-$54.43M$3.26B$265.48M
7 Day Performance5.60%0.22%0.69%1.22%
1 Month Performance2.08%5.59%2.48%0.39%
1 Year Performance-64.60%9.98%27.93%23.47%

Adverum Biotechnologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADVM
Adverum Biotechnologies
4.0606 of 5 stars
$2.45
-2.8%
$23.80
+871.4%
-63.7%$52.65M$1M-0.38190Upcoming Earnings
RAPT
Rapt Therapeutics
4.1478 of 5 stars
$12.67
-4.8%
$21.67
+71.0%
-46.8%$220.09MN/A-0.6680
MDWD
MediWound
2.1759 of 5 stars
$19.93
-2.0%
$32.25
+61.8%
+14.9%$219.72M$20.22M-9.5480Upcoming Earnings
Gap Up
TLSA
Tiziana Life Sciences
0.2821 of 5 stars
$1.95
+4.8%
N/A+49.3%$217.34MN/A0.008
ELDN
Eledon Pharmaceuticals
1.6755 of 5 stars
$3.23
-10.8%
$10.00
+209.6%
+5.4%$216.77MN/A-1.5410Gap Down
High Trading Volume
DMAC
DiaMedica Therapeutics
1.4397 of 5 stars
$5.06
+0.2%
$10.75
+112.5%
+48.3%$216.56MN/A-7.9120Upcoming Earnings
YMAB
Y-mAbs Therapeutics
2.2872 of 5 stars
$4.88
+2.3%
$15.60
+219.7%
-22.5%$216M$87.68M-7.63150Trending News
Upcoming Earnings
Analyst Downgrade
NLTX
Neoleukin Therapeutics
N/A$22.72
-0.4%
N/A-43.8%$213.52MN/A-7.3190
CRBU
Caribou Biosciences
2.4543 of 5 stars
$2.29
+0.4%
$8.50
+271.2%
-4.7%$212.05M$9.99M-1.41100Gap Up
FDMT
4D Molecular Therapeutics
2.5044 of 5 stars
$4.64
+1.5%
$29.56
+537.0%
-60.7%$211.70M$40K-1.46120
ALMS
Alumis
2.0316 of 5 stars
$4.04
+4.1%
$19.80
+390.1%
-64.4%$211.09MN/A0.00N/AUpcoming Earnings
High Trading Volume

Related Companies and Tools


This page (NASDAQ:ADVM) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners